


JNK-IN-14

Cat. No.:	HY-156182
Molecular Formula:	C ₂₇ H ₃₁ N ₅ O ₄ S
Molecular Weight:	521.63
Target:	JNK; Cytochrome P450
Pathway:	MAPK/ERK Pathway; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JNK-IN-14 is a potent JNK inhibitor with IC ₅₀ values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis. JNK-IN-14 shows cell population arrest at the G2/M phase and slightly inhibits beclin-1 production at K562 leukemia cells relative to SP600125 (HY-12041), showing higher inhibitory ability. ^[1]																			
IC₅₀ & Target	JNK1 1.82 nM (IC ₅₀)	JNK2 10.5 nM (IC ₅₀)	JNK3 10.5 nM (IC ₅₀)	CYP2D6 26.7 ± 0.5 nM (IC ₅₀)																
	CYP3A4 383.0 ± 1. nM (IC ₅₀)																			
In Vitro	<p>JNK-IN-14 (compound 11e) (2.5 μM-5 μM, 24 h) leads to slight early-stage apoptosis in a concentration-dependent manner in K562 cells^[1].</p> <p>JNK-IN-14 (1.25-5 μM, 24 h) arrests cell population in K562 at higher concentrations in comparison with SP600125, showing higher inhibitory ability.^[1]</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 Human Leukemia Cell</td> </tr> <tr> <td>Concentration:</td> <td>2.5 μM, 5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Resulted in early-stage apoptosis with 1.94%, and 2.14% for 2.5 and 5 μM, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 human leukemia cell</td> </tr> <tr> <td>Concentration:</td> <td>1.25 μM, 2.56 μM, 5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed viable cells arrest at the G2/M phase with values of 45.33% at 1.25 μM, 2.5 μM at 62.99%, and 5 μM at 98.97%.</td> </tr> </table>				Cell Line:	K562 Human Leukemia Cell	Concentration:	2.5 μM, 5 μM	Incubation Time:	24 h	Result:	Resulted in early-stage apoptosis with 1.94%, and 2.14% for 2.5 and 5 μM, respectively.	Cell Line:	K562 human leukemia cell	Concentration:	1.25 μM, 2.56 μM, 5 μM	Incubation Time:	24 h	Result:	Showed viable cells arrest at the G2/M phase with values of 45.33% at 1.25 μM, 2.5 μM at 62.99%, and 5 μM at 98.97%.
Cell Line:	K562 Human Leukemia Cell																			
Concentration:	2.5 μM, 5 μM																			
Incubation Time:	24 h																			
Result:	Resulted in early-stage apoptosis with 1.94%, and 2.14% for 2.5 and 5 μM, respectively.																			
Cell Line:	K562 human leukemia cell																			
Concentration:	1.25 μM, 2.56 μM, 5 μM																			
Incubation Time:	24 h																			
Result:	Showed viable cells arrest at the G2/M phase with values of 45.33% at 1.25 μM, 2.5 μM at 62.99%, and 5 μM at 98.97%.																			

REFERENCES

[1]. Karim I Mersal, et al. Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells. *Eur J Med Chem.* 2023 Sep 15;261:115779.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA